AbbVie's Etentamig Shows Promise in Phase 3 Study for Multiple Myeloma Treatment

AbbVie has announced an update on its ongoing Phase 3 clinical study of etentamig for relapsed or refractory multiple myeloma. The study aims to evaluate the efficacy of etentamig compared to standard available therapies. With positive results, AbbVie could enhance its oncology portfolio, boosting stock performance and investor confidence. The study is ongoing, with further details available on the ClinicalTrials portal.

AbbVie (ABBV) has announced an update on its ongoing Phase 3 clinical study of etentamig for relapsed or refractory multiple myeloma. The study, titled "A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Etentamig (ABBV-383) Monotherapy in Japanese Subjects With Relapsed or Refractory Multiple Myeloma (4L+ RRMM Monotherapy Study)," aims to assess the efficacy of etentamig compared to standard available therapies [1].

Etentamig is an investigational drug administered intravenously and is being tested in two increasing doses to determine a tolerable dose for treating relapsed or refractory multiple myeloma (R/R MM). The study began on March 24, 2022, and is currently active but not recruiting, with the last update on August 7, 2025 [1].

The results of this study could significantly influence AbbVie's stock performance and investor sentiment. Positive outcomes may enhance the company's position in the competitive multiple myeloma treatment market, where the global market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11% [2].

The market growth is driven by rising multiple myeloma cases, advances in targeted therapies like monoclonal antibodies, and the increasing adoption of immunotherapies. Enhanced diagnostics and greater healthcare accessibility are also boosting market expansion [2].

Investors should closely monitor this development, considering the broader industry context. The study is ongoing, and further details are available on the ClinicalTrials portal.

References:
[1] https://www.theglobeandmail.com/investing/markets/stocks/ABBV/pressreleases/34029251/abbvies-phase-1-study-on-etentamig-for-multiple-myeloma-key-insights-for-investors/
[2] https://finance.yahoo.com/news/multiple-myeloma-market-trends-company-105900693.html